Cue Biopharma (CUE) Other Non-Current Assets (2017 - 2025)
Cue Biopharma (CUE) posted Other Non-Current Assets of $94000.0 for Q4 2025, down 38.56% sequentially from $153000.0 in Q3 2025, and down 10.48% YoY from $105000.0 in Q4 2024.
Cue Biopharma (CUE) Other Non-Current Assets (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Other Non-Current Assets for 9 years, with the latest figure at $94000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 10.48% year-over-year to $94000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $94000.0 (down 10.48% YoY) and the FY2025 annual result came in at $94000.0, down 10.48% from the prior year.
- Other Non-Current Assets declined to $94000.0 in Q4 2025 per CUE's latest filing, from $153000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.8 million in Q2 2022 and troughed at $94000.0 in Q4 2025.
- A 5-year average of $1.1 million and a median of $151000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 2431.33% in 2022, then tumbled 96.76% in 2023.
- Over 5 years, Other Non-Current Assets stood at $2.7 million in 2021, then increased by 14.52% to $3.1 million in 2022, then tumbled by 95.15% to $151000.0 in 2023, then sank by 30.46% to $105000.0 in 2024, then decreased by 10.48% to $94000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $94000.0, $153000.0, and $153000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 628,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 94,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 153,000.00 |
| Mar 31, 2025 | 1.96 Mn |
| Dec 31, 2024 | 105,000.00 |
| Sep 30, 2024 | 108,000.00 |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 114,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Sep 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Dec 31, 2022 | 3.12 Mn |
| Sep 30, 2022 | 3.12 Mn |
| Jun 30, 2022 | 3.80 Mn |
| Mar 31, 2022 | 137,000.00 |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 143,000.00 |
| Jun 30, 2021 | 150,000.00 |
| Mar 31, 2021 | 2.58 Mn |
| Dec 31, 2020 | 150,000.00 |